The Cardiology Advisor

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
Fierce Pharma

Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
Healio

Optimizing mavacamten for treatment of obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Nasdaq

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...